Albuquerque, NM, March 31, 2017. Agilvax, Inc., a biotechnology company that is developing novel cancer stem cell targeting immunotherapies, announced today that Dr. John O’Rourke, Director of Oncology, will be presenting a poster, AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT, at the American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, DC, April 1-5, 2017. Additionally, Agilvax’s key collaborator, Dr. Federica Cavallo, from the University of Turin will be presenting data during her presentation, The cystine/glutamate antitporter (xCT): A new cancer stem cell target for anticancer vaccines.

Poster

Session Category: Immunology
Session Title: Enzymes and Hormones and Metabolism in Tumor Immunity
Date and Time: Wednesday Apr 5, 2017 8:00 AM – 12:00 PM
Location: Convention Center, Halls A-C, Poster Section 24
Poster Board No: 4
Poster Title: AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT

Presentation

Session Type: Recent Advances in Prevention Research
Session Title: Premalignant Lesions as Targets for Immunoprevention
Session Start Time: Tuesday, April 4, 2017, 1:00 PM
Session End Time: Tuesday, April 4, 2017, 2:45 PM
Location: Ballroom C, Level 3, Washington Convention Center
CME Status: CME-Designated Session
Presentation Title: The cystine/glutamate antiporter (xCT): A new cancer stem cell target for anticancer vaccines